OptiRTP Schedules Meetings with Two Pharmaceutical Companies to Discuss Co-Therapy Applications
OptiRTP has scheduled meetings with two established New Zealand pharmaceutical companies in January 2026 to discuss potential co-therapy applications for its Optimum Bio Sound Therapy (OBST) neuromodulation platform.
The discussions will focus on how OBST could be integrated as a supportive therapy alongside existing pharmaceutical treatments, with initial emphasis on improving patient tolerability and wellbeing outcomes.
Both companies have international distribution networks and experience across multiple therapeutic areas. OptiRTP has identified oncology supportive care as an initial area of focus, where non-invasive technologies may help address unmet needs in patient comfort during treatment.
The meetings represent OptiRTP’s first formal discussions with pharmaceutical companies regarding co-therapy integration.
About OptiRTP
OptiRTP is a New Zealand health-technology company developing Optimum Bio Sound Therapy (OBST), a neuromodulation platform registered as an FDA Class I medical device. The platform has delivered over 200,000 therapy hours to more than 1,100 users. www.optirtp.com
